ESPERION Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock

Stock Information for Esperion Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Esperion Therapeutics Inc.

Esperion to Report First Quarter 2024 Financial Results on May 7
U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
RFK, Esperion Therapeutics Announce 2024 Promotional Schedule

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.